We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into West Pharmaceutical (WST) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that West Pharmaceutical Services (WST - Free Report) will report quarterly earnings of $1.78 per share in its upcoming release, pointing to a year-over-year increase of 0.6%. It is anticipated that revenues will amount to $738.9 million, exhibiting an increase of 4.3% compared to the year-ago quarter.
Over the last 30 days, there has been an upward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific West Pharmaceutical metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales- Contract-Manufactured Products' reaching $132.82 million. The estimate indicates a year-over-year change of +7.2%.
It is projected by analysts that the 'Net Sales- Proprietary Products' will reach $604.89 million. The estimate indicates a year-over-year change of +3.4%.
Analysts predict that the 'Gross Profit- Proprietary Products' will reach $249.13 million. Compared to the current estimate, the company reported $243 million in the same quarter of the previous year.
Analysts forecast 'Gross Profit- Contract-Manufactured Products' to reach $22.26 million. Compared to the present estimate, the company reported $19.10 million in the same quarter last year.
Shares of West Pharmaceutical have experienced a change of +18.1% in the past month compared to the +5.8% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), WST is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into West Pharmaceutical (WST) Q4: Wall Street Projections for Key Metrics
Wall Street analysts forecast that West Pharmaceutical Services (WST - Free Report) will report quarterly earnings of $1.78 per share in its upcoming release, pointing to a year-over-year increase of 0.6%. It is anticipated that revenues will amount to $738.9 million, exhibiting an increase of 4.3% compared to the year-ago quarter.
Over the last 30 days, there has been an upward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific West Pharmaceutical metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales- Contract-Manufactured Products' reaching $132.82 million. The estimate indicates a year-over-year change of +7.2%.
It is projected by analysts that the 'Net Sales- Proprietary Products' will reach $604.89 million. The estimate indicates a year-over-year change of +3.4%.
Analysts predict that the 'Gross Profit- Proprietary Products' will reach $249.13 million. Compared to the current estimate, the company reported $243 million in the same quarter of the previous year.
Analysts forecast 'Gross Profit- Contract-Manufactured Products' to reach $22.26 million. Compared to the present estimate, the company reported $19.10 million in the same quarter last year.
View all Key Company Metrics for West Pharmaceutical here>>>
Shares of West Pharmaceutical have experienced a change of +18.1% in the past month compared to the +5.8% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), WST is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>